Mounjaro vs Wegovy India in India — molecule, dose, price
Mounjaro vs Wegovy India in India: molecule, manufacturer, dose range, price range, and questions to ask your doctor.
Overview
Mounjaro vs Wegovy in India: A Structural Comparison
If your doctor mentioned both Mounjaro and Wegovy, you're likely trying to understand how they differ. This page is a structural comparison — it lays out what's the same and what's different between the two brands as they exist in India. It is not a prescription, not a recommendation, and not a guide for switching medications on your own.
The most important thing to know up front: Mounjaro and Wegovy use different molecules. Mounjaro contains tirzepatide (a dual GIP + GLP-1 agonist made by Eli Lilly), while Wegovy contains semaglutide (a GLP-1 agonist made by Novo Nordisk). Both are CDSCO-approved weekly injections, both follow titration schedules, and both are available in India through licensed pharmacists — but their mechanisms, dose ladders, and pricing differ.
For current Indian pricing on both brands, see /price. For dose-step planning, see /tools/titration. Final choice always rests with your prescriber.
At a glance
| Mounjaro | Wegovy | |
|---|---|---|
| Molecule | Tirzepatide (dual GIP + GLP-1) | Semaglutide (GLP-1 only) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Available doses in India | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg | 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg |
| Indian price range | See [/price](/price) | See [/price](/price) |
| Cadence | Once weekly | Once weekly |
| Titration interval | ~4 weeks per step | ~4 weeks per step |
| CDSCO approval | Yes | Yes |
What's the same
What's structurally the same
Despite different molecules, Mounjaro and Wegovy share a lot of structure:
- Weekly subcutaneous injection. Both are once-weekly pens — not daily, not oral.
- GLP-1 pathway. Both act on the GLP-1 receptor (Wegovy exclusively; Mounjaro alongside its GIP action).
- CDSCO-approved in India. Both are licensed for use in India and dispensed by registered pharmacists against a valid prescription.
- Step-up titration. Both start at a low introductory dose and increase roughly every 4 weeks under a clinician's supervision. See /tools/titration for how step intervals are typically structured.
- Similar side-effect categories. GI effects — nausea, constipation, reflux — are commonly reported on both. The intensity profile differs, but the family of effects overlaps.
- Prescription-only. Neither is available over-the-counter from Apollo, Tata 1mg, Pharmeasy, or Netmeds without a valid Rx.
Before starting either brand, many patients use /check to review readiness questions with their doctor.
What's different
What's structurally different
Molecule and mechanism. Mounjaro's tirzepatide is a dual agonist — it activates both the GIP and GLP-1 receptors. Wegovy's semaglutide is a single GLP-1 agonist. Studies describe different average weight-loss outcomes between the two molecules, but individual response varies and your doctor is the right person to interpret what that means in your case.
Half-life and pharmacokinetics. Both are engineered for weekly dosing, but tirzepatide and semaglutide have distinct half-lives and binding profiles — the label for each describes the specifics.
Dose ladder. Mounjaro's ladder runs 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Wegovy's ladder runs 0.25 → 0.5 → 1 → 1.7 → 2.4 mg. The numbers are not comparable — they reflect different molecules at different potencies.
Manufacturer and supply chain in India. Mounjaro is supplied by Eli Lilly; Cipla also markets tirzepatide under Yurpeak. Wegovy is supplied by Novo Nordisk; semaglutide is also available in India as Semaglyn (Zydus) and Obeda (Dr Reddy's). Availability across Apollo, Tata 1mg, Pharmeasy, and Netmeds shifts month to month.
Pricing. Both sit in the premium price band in ₹ terms, and the relative cost can flip depending on dose. Current ranges live at /price.
Side-effect profile detail. See /guides/tirzepatide-side-effects for Mounjaro and /guides/semaglutide-side-effects for Wegovy.
Questions to ask your doctor
Questions to bring to your doctor
Use these as conversation prompts at your next consultation — not as a script to self-decide:
- Given my medical history, is there a structural reason one molecule fits my situation better than the other?
- What does the titration timeline look like for me on this brand, and when would we review progress?
- Which brand has more reliable supply at my local pharmacist or on Apollo / Tata 1mg right now?
- If I tolerate the starting dose poorly, what are the typical next steps?
- Are there interactions with my current medications I should know about?
- What monitoring (labs, follow-up visits) will I need on either option?
If cost is a constraint, ask openly — there may be CDSCO-approved alternatives within the same molecule family (e.g., Yurpeak for tirzepatide, Semaglyn or Obeda for semaglutide) worth discussing.
Frequently asked questions
Can I switch from Mounjaro to Wegovy (or vice versa)?
Switching between molecules is a clinical decision, not a self-managed one. The dose ladders don't map onto each other — 5mg of Mounjaro is not equivalent to any single Wegovy dose. If you're considering a switch (often due to availability, tolerability, or cost in ₹), bring it up with your prescriber. They will typically restart titration on the new molecule rather than transfer a 'matching' dose. Please consult your doctor before making any change.
Which is more available in India right now?
Availability shifts month to month across Apollo, Tata 1mg, Pharmeasy, and Netmeds. Mounjaro (Eli Lilly) and its Cipla counterpart Yurpeak have been more visible on Indian pharmacist shelves through 2024–25, while Wegovy launched in India more recently via Novo Nordisk. Semaglyn (Zydus) and Obeda (Dr Reddy's) are additional semaglutide options. Your local pharmacist can confirm current stock.
Are the side effects different between Mounjaro and Wegovy?
The *categories* overlap — nausea, constipation, reflux, fatigue are commonly reported on both. The *intensity and frequency* can differ because the molecules are different. The label for each brand describes specifics. See [/guides/tirzepatide-side-effects](/guides/tirzepatide-side-effects) and [/guides/semaglutide-side-effects](/guides/semaglutide-side-effects). Anything persistent or severe should be reviewed with your doctor.
Which is cheaper in India?
It depends on the dose. Both Mounjaro and Wegovy sit in the premium ₹ band, and which is cheaper at a given step varies. Generic-brand tirzepatide (Yurpeak) and generic-brand semaglutide (Semaglyn, Obeda) may shift the math further. Current ranges are tracked at [/price](/price).
Do both require the same kind of prescription in India?
Yes. Both are prescription-only CDSCO-regulated medications. A licensed Indian pharmacist — whether physical or through Apollo, Tata 1mg, Pharmeasy, or Netmeds — will require a valid Rx for either brand. Neither is sold over the counter. If a seller offers either without a prescription, that's a red flag to look for.
If both are GLP-1 medications, why does the molecule matter?
Mounjaro's tirzepatide engages two receptor pathways (GIP and GLP-1), while Wegovy's semaglutide engages one (GLP-1). Studies describe different efficacy and tolerability profiles as a result. For an individual patient, the structural difference can matter clinically — which is why the choice belongs with your doctor, not a comparison page. Please consult your doctor to understand which fits your situation.
Glipin is a tracking and educational tool. We are not your doctor and we do not give medical advice. We do not guarantee any pen is authentic. Always consult a licensed healthcare professional about your treatment.